Thyroid Eye Disease
Conditions
Keywords
Graves Disease, Rituximab
Brief summary
Thyroid eye disease (TED) is an autoimmune inflammation of the orbital tissues that develops in up to 50% of patients with Graves' disease. Although about 80% respond to IVGC initially, the relapse rate is high and about 75% require further surgery despite initial response. Although the natural history of TED is associated with spontaneous remissions after about 1 to 3 years, many irreversible serious ophthalmic and orbital complications can arise during this time. Therefore, there is a need for improved intervention strategies in the early active inflammatory phase of TED, to avoid progression to the cicatricial stage where disease manifestations can only be addressed in a rehabilitative fashion. The primary immunopathogenesis of Graves' disease is considered to be activation of B cells that then produce autoantibody against thyrotropin receptors in the thyroid (TRAb). Like in many autoimmune diseases, the inflammatory CD4+ T cell subset known as Th17 cells is also increased in blood of patients with active Graves' disease; the putative Th17 cytokine, IL-17, is also increased in serum and tears of TED patients. There is also an emerging pathogenic role for Th17 cells that co-express the chemokine receptor CXCR5 and drive autoantibody production. The contribution of Th17 cells to TED is not well defined. This study is an observational, longitudinal, prospective study of patients receiving treatment for thyroid eye disease.
Detailed description
All enrolled subjects will receive Intravenous Glucocorticoid (IVGC) therapy, which is currently the standard of care for TED patients. Subjects will receive the IVGC therapy at a facility chosen by them and their physician. If their disease does not respond to IVGC therapy, they will receive rituximab and/or surgical decompression and/or radiation which is also currently standard of care at a facility chosen by them and their physician. Prior to initiation of treatment and during the course of treatment, study patients will get research labs done along with routine labs and fill out questionnaires regarding their disease symptoms. We will obtain 30 mL or 2 tablespoons of blood from subjects at initial evaluation and approximately Wk4, Wk 12, Wk 26, Wk 38, and Wk 52 (this may vary depending on when the patient comes in for their follow up visits, but the schedule approximates what is typical for standard of care in these patients) for mechanistic studies.
Interventions
None listed
Sponsors
University of Pittsburgh
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Willing and able to give informed consent 2. Age 18 to 75 years of age 3. Diagnosis of Thyroid Eye Disease (TED) with a CAS of ≥ 3. (Thyroid status can be euthyroid, hyper or hypothyroid.) 4. Willingness to practice birth control for at least 12 months post treatment. 5. Normal organ function, except if abnormal due to tumor involvement. 6. Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for twelve months after completion of treatment. 7. Subject has provided written informed consent. 8. Documentation of CD20 + status (for B cell malignancies). 9. ANC: \> 1000/mm3 10. Adequate bone marrow function as indicated by a total white blood cell count of \> 4 x 109/, hemoglobin of \> 7 g/dl or a platelet count \>100,000/mm³ 11. Adequate renal function as indicated by creatinine of \<2.5. 12. Adequate liver function, as indicated by AST or ALT \<2x Upper Limit of normal unless related to primary disease.
Exclusion criteria
Patients will be excluded from the study based on the following criteria: 1. Brittle insulin dependent diabetes \[The term brittle refers to cases of diabetes in which there is an instability that leads to a disruption of life and often recurrent and/ or prolonged hospitalization\] 2. Pregnant or nursing patients 3. Significant medical comorbidities that would make the risk of high dose steroids intolerable such as severe CHF, CAD, arrhythmias, renal insufficiency, infection or immune deficiency, systemic autoimmune disease, severe glaucoma etc. 4. Absolute neutrophil count \< 1500/mm³. 5. Contraindication to use of rituximab 6. Positive PPD and/or Quantiferon Gold TB test without prior anti-tuberculous therapy; active TB 7. HIV or hepatitis infection or declined consent for HIV or hepatitis testing 8. Use of rituximab in the prior 24 months for any reason other than TED 9. Unwillingness to practice birth control for at least 12 months post treatment 10. Pregnancy (a negative serum pregnancy test should be performed for all women of childbearing potential within 7 days of treatment), or lactating. 11. Inability to comply with study and/or follow-up procedures. 12. History of HIV. 13. Presence of active infection. 14. Presence of CNS metastases. 15. New York Heart Association Classification III or IV heart disease (See Appendix D). 16. Concomitant malignancies or previous malignancies within the last five years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. 17. History of psychiatric disorder. 18. At the Investigator's discretion, receipt of a live vaccine within 4 weeks prior to randomization.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Remission of disease activity (decrease in CAS of ≥ 2) at 26 weeks after first rituximab/placebo infusion | 26 weeks | Remission of symptoms and disease activity by 26 weeks after the first dose of medication. Subjects will be followed for one year to assess relapse |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Remission of disease activity (decrease in CAS of ≥ 2) at 6 and 14 weeks after first rituximab/placebo infusion. | 6 weeks | Remission of symptoms by week 6 after treatment and again at week 14. |
| Maintenance of CAS (defined as no worsening of CAS or requirement of other interventions such as surgical decompression/orbital radiation by 26 weeks after first rituximab/placebo infusion . | 26 weeks | Maintaining an absence of symptoms and disease activity. |
| Improvement in disease activity, as measured by CAS as a continuous variable at 6, 14, 26, 38 and 52 weeks after first infusion of rituximab, | 1 year | Improvement in symptoms and disease activity |
| ll adverse effects related to RTX | 1 year | Tracking any adverse events or serious adverse events related to rituximab. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Efficacy outcome as measured by Time to ≥ 2 points improvement on the CAS. | 1 year | Time to ≥ 2 points improvement on the CAS. |
| Efficacy outcome as measured by Immunologic markers and mechanistic analyses to include studies of peripheral blood and thyroid B and T cells and autoantibody levels, thyroid volume, cellularity and function. | 1 year | Immunologic markers and mechanistic analyses to include studies of peripheral blood and thyroid B and T cells and autoantibody levels, thyroid volume, cellularity and function. |
| Efficacy outcome as measured by Decrease in exophthalmos (measured in mm using the same Hertel exophthalmometer and same intercanthal distance for an individual patient). | 1 year | Decrease in exophthalmos (measured in mm using the same Hertel exophthalmometer and same intercanthal distance for an individual patient). |
| Efficacy outcome | 1 year | Decrease in lid aperture (distance between the lid margins in mm with patient looking in the primary position, sitting relaxed and with distant fixation). |
| Efficacy outcome as measured by Subjective diplopia score | 1 year | Subjective diplopia score (0=no diplopia; 1=intermittent, i.e. diplopia in primary position of gaze, when tired or when first awakening; 2= inconstant, i.e. diplopia at extremes of gaze; 3=constant, i.e. continuous diplopia in primary or reading position). |
| Efficacy outcome as measured by Improvement in quality of life as measured by an SF-36 and GoQoL. | 1 year | Improvement in quality of life as measured by an SF-36 and GoQoL. |
Countries
United States
Outcome results
None listed